Cargando…

Human papillomavirus vaccination induces neutralising antibodies in oral mucosal fluids

BACKGROUND: Mucosal human papillomaviruses (HPV) are a major cause of cancers and papillomas of the anogenital and oropharyngeal tract. HPV-vaccination elicits neutralising antibodies in sera and cervicovaginal secretions and protects uninfected individuals from persistent anogenital infection and a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Handisurya, A, Schellenbacher, C, Haitel, A, Senger, T, Kirnbauer, R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815771/ https://www.ncbi.nlm.nih.gov/pubmed/26867163 http://dx.doi.org/10.1038/bjc.2015.462

Ejemplares similares

Sialyl-Tn vaccine induces antibody-mediated tumour protection in a relevant murine model
por: Julien, S, et al.
Publicado: (2009)

Dual inhibition of EGFR and mTOR pathways in small cell lung cancer
por: Schmid, K, et al.
Publicado: (2010)

Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV)
por: Huber, Bettina, et al.
Publicado: (2017)

Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours
por: Ahlskog, J K J, et al.
Publicado: (2009)

Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets
por: Wattenberg, M M, et al.
Publicado: (2014)

HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo
por: Pukac, L, et al.
Publicado: (2005)

A Chimeric 18L1-45RG1 Virus-Like Particle Vaccine Cross-Protects against Oncogenic Alpha-7 Human Papillomavirus Types
por: Huber, Bettina, et al.
Publicado: (2015)

Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation
por: Hendrikx, J J M A, et al.
Publicado: (2014)

Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection
por: Viala, Marie, et al.
Publicado: (2018)

Inhibition of ICAM2 induces radiosensitisation in oral squamous cell carcinoma cells
por: Ishigami, T, et al.
Publicado: (2008)

Identification of Lck-derived peptides applicable to anti-cancer vaccine for patients with human leukocyte antigen-A3 supertype alleles
por: Naito, M, et al.
Publicado: (2007)

Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer
por: Ruf, P, et al.
Publicado: (2007)

The development and characterisation of porphyrin isothiocyanate–monoclonal antibody conjugates for photoimmunotherapy
por: Hudson, R, et al.
Publicado: (2005)

Characterisation and internalisation of recombinant humanised HMFG-1 antibodies against MUC1
por: Pericleous, L M, et al.
Publicado: (2005)

Efficacy of RG1-VLP Vaccination against Infections with Genital and Cutaneous Human Papillomaviruses
por: Schellenbacher, Christina, et al.
Publicado: (2013)

A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer
por: Veltkamp, S A, et al.
Publicado: (2006)

A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels
por: Palumbo, A, et al.
Publicado: (2011)

Temozolomide induces senescence but not apoptosis in human melanoma cells
por: Mhaidat, N M, et al.
Publicado: (2007)

The antibody-based targeted delivery of TNF in combination with doxorubicin eradicates sarcomas in mice and confers protective immunity
por: Hemmerle, T, et al.
Publicado: (2013)

Antibody targeting of CD24 efficiently retards growth and influences cytokine milieu in experimental carcinomas
por: Salnikov, A V, et al.
Publicado: (2013)

Vaccination with Mage-b DNA induces CD8 T-cell responses at young but not old age in mice with metastatic breast cancer
por: Castro, F, et al.
Publicado: (2009)

Prevalence of potential drug–drug interactions in cancer patients treated with oral anticancer drugs
por: van Leeuwen, R W F, et al.
Publicado: (2013)

Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies
por: Diaz Miqueli, A, et al.
Publicado: (2009)

Functional identity of receptors for proteolysis-inducing factor on human and murine skeletal muscle
por: Mirza, K A, et al.
Publicado: (2014)

CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers
por: Smith, L M, et al.
Publicado: (2008)

Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40
por: Oflazoglu, E, et al.
Publicado: (2009)

Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-β and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation
por: Vlahovic, G, et al.
Publicado: (2006)

Enhancing the immunogenicity of tumour lysate-loaded dendritic cell vaccines by conjugation to virus-like particles
por: Win, S J, et al.
Publicado: (2012)

Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells
por: Caiazza, F, et al.
Publicado: (2015)

Characterisation and radioimmunotherapy of L19-SIP, an anti-angiogenic antibody against the extra domain B of fibronectin, in colorectal tumour models
por: El-Emir, E, et al.
Publicado: (2007)

FAT1: a potential target for monoclonal antibody therapy in colon cancer
por: Pileri, Piero, et al.
Publicado: (2016)

The therapeutic potential of a series of orally bioavailable anti-angiogenic microtubule disruptors as therapy for hormone-independent prostate and breast cancers
por: Newman, S P, et al.
Publicado: (2007)

Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR
por: Panousis, C, et al.
Publicado: (2005)

Overexpression of cIAP2 contributes to 5-FU resistance and a poor prognosis in oral squamous cell carcinoma
por: Nagata, M, et al.
Publicado: (2011)

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer
por: Rowland, A, et al.
Publicado: (2015)

Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours
por: Campone, M, et al.
Publicado: (2009)

A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer
por: Wentink, Madelon Q, et al.
Publicado: (2016)

Anti-HER-2 DNA vaccine protects Syrian hamsters against squamous cell carcinomas
por: Berta, G N, et al.
Publicado: (2005)

Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody
por: Osada, T, et al.
Publicado: (2010)

Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines
por: Wang, Y, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_h8j0a15r4bs4etihd9nm0nm5uh